Download PDF
Semin Thromb Hemost
DOI: 10.1055/a-2799-0557
Review Article

Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers

Authors

  • Charlotte Gran 

    1   Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden
    2   Clinical Chemistry, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden

  • Sanna Norén

    3   Department of Medicine Huddinge, Gastroenterology and Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
    4   Department of Hepatology, Karolinska University Hospital, Stockholm, Sweden

  • Jovan P. Antovic

    1   Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden
    2   Clinical Chemistry, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden

Funding Information This work was supported by the Swedish Cancer Society (Grant Number 22 2109Fk).
Further Information
   Permissions and Reprints

Abstract

Coagulopathies are common in hematological malignancies and can cause life-threatening bleeding or thrombosis. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, carry cargo that reflects their cellular origin. They frequently express tissue factor (TF) and expose phosphatidylserine (PS), which initiate and amplify coagulation and can also transport fibrinolytic mediators that modulate plasmin generation. Procoagulant EVs are commonly assessed using TF- and PS-dependent functional assays, global hemostasis tests such as overall hemostatic potential, and flow cytometric phenotyping. Clinical and experimental data show elevated EV numbers and activity at diagnosis in several hematological malignancies. In acute leukemias, EV-associated procoagulant activity often declines with treatment yet may remain above control levels, consistent with residual risk. In plasma cell disorders and myeloproliferative neoplasms, platelet-derived and TF/PS-positive EVs are frequently increased and have been linked to enhanced thrombin generation. EVs appear to play key roles across leukemias, multiple myeloma, lymphoid, and myeloproliferative neoplasms. However, considerable methodological heterogeneity, including differences in preanalytical handling, EV isolation, characterization, and activity measurement, limits comparability and clinical translation. Disease-specific mechanistic studies are needed to clarify how EVs modulate hemostasis in different hematologic malignancies. In parallel, standardized protocols and adequately powered clinical studies are required to validate EVs as biomarkers.

Keywords

cancer and thrombosis/hemostasis - hypercoagulability - thrombosis - mechanistic - laboratory diagnostics - extracellular vesicle


Publication History

Received: 06 October 2025

Accepted: 27 January 2026

Accepted Manuscript online:
12 February 2026

Article published online:
24 February 2026

© 2026. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27 (29) 4848-4857
    Search in Google Scholar
  • 2 Dimopoulos M, Spencer A, Attal M. et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357 (21) 2123-2132
    Search in Google Scholar
  • 3 Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364 (11) 1046-1060
    Search in Google Scholar
  • 4 Grace RF, Dahlberg SE, Neuberg D. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011; 152 (04) 452-459
    Search in Google Scholar
  • 5 Sanz MA, Grimwade D, Tallman MS. et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (09) 1875-1891
    Search in Google Scholar
  • 6 Hermsen J, Hambley B. The coagulopathy of acute promyelocytic leukemia: an updated review of pathophysiology, risk stratification, and clinical management. Cancers (Basel) 2023; 15 (13) 3477
    Search in Google Scholar
  • 7 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122 (13) 2176-2184
    Search in Google Scholar
  • 8 van Genderen PJ, Leenknegt H, Michiels JJ, Budde U. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl. 01) 79-82
    Search in Google Scholar
  • 9 Awada H, Voso MT, Guglielmelli P, Gurnari C. Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers (Basel) 2020; 12 (07) 1746
    Search in Google Scholar
  • 10 Bouvy C, Gheldof D, Chatelain C, Mullier F, Dogné JM. Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. J Extracell Vesicles 2014; 3: 3
    Search in Google Scholar
  • 11 Hisada Y, Mackman N. Tissue factor and extracellular vesicles: activation of coagulation and impact on survival in cancer. Cancers (Basel) 2021; 13 (15) 3839
    Search in Google Scholar
  • 12 Khalife J, Sanchez JF, Pichiorri F. Extracellular vesicles in hematological malignancies: from biomarkers to therapeutic tools. Diagnostics (Basel) 2020; 10 (12) 1065
    Search in Google Scholar
  • 13 Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200 (04) 373-383
    Search in Google Scholar
  • 14 van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012; 64 (03) 676-705
    Search in Google Scholar
  • 15 Caivano A, La Rocca F, Laurenzana I. et al. Extracellular vesicles in hematological malignancies: from biology to therapy. Int J Mol Sci 2017; 18 (06) 1183
    Search in Google Scholar
  • 16 Ball S, Nugent K. Microparticles in hematological malignancies: role in coagulopathy and tumor pathogenesis. Am J Med Sci 2018; 355 (03) 207-214
    Search in Google Scholar
  • 17 Lipets EN, Antonova OA, Shustova ON, Losenkova KV, Mazurov AV, Ataullakhanov FI. Use of thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation. PLoS One 2020; 15 (05) e0227932
    Search in Google Scholar
  • 18 Catani L, Cavo M, Palandri F. The power of extracellular vesicles in myeloproliferative neoplasms: “crafting” a microenvironment that matters. Cells 2021; 10 (09) 2316
    Search in Google Scholar
  • 19 Sinauridze EI, Kireev DA, Popenko NY. et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97 (03) 425-434
    Search in Google Scholar
  • 20 Karantanou C, Minciacchi VR, Karantanos T. Extracellular vesicles in myeloid neoplasms. Int J Mol Sci 2022; 23 (15) 8827
    Search in Google Scholar
  • 21 Rautou PE, Mackman N. Deletion of microvesicles from the circulation. Circulation 2012; 125 (13) 1601-1604
    Search in Google Scholar
  • 22 Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7 (08) 1421-1423
    Search in Google Scholar
  • 23 Owens III AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108 (10) 1284-1297
    Search in Google Scholar
  • 24 Hisada Y, Mackman N. Measurement of tissue factor activity in extracellular vesicles from human plasma samples. Res Pract Thromb Haemost 2018; 3 (01) 44-48
    Search in Google Scholar
  • 25 Jing H, Wu X, Xiang M, Wang C, Novakovic VA, Shi J. Microparticle phosphatidylserine mediates coagulation: involvement in tumor progression and metastasis. Cancers (Basel) 2023; 15 (07) 1957
    Search in Google Scholar
  • 26 Lacroix R, Plawinski L, Robert S. et al. Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis. Haematologica 2012; 97 (12) 1864-1872
    Search in Google Scholar
  • 27 Berckmans RJ, Lacroix R, Hau CM, Sturk A, Nieuwland R. Extracellular vesicles and coagulation in blood from healthy humans revisited. J Extracell Vesicles 2019; 8 (01) 1688936
    Search in Google Scholar
  • 28 Lacroix R, Judicone C, Souab KH. et al. The procoagulant and fibrinolytic balance of extracellular vesicles predicts mortality in septic shock patients. J Extracell Vesicles 2025; 14 (06) e70073
    Search in Google Scholar
  • 29 Witwer KW, Buzás EI, Bemis LT. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2013; 2: 2
    Search in Google Scholar
  • 30 Coumans FAW, Brisson AR, Buzas EI. et al. Methodological guidelines to study extracellular vesicles. Circ Res 2017; 120 (10) 1632-1648
    Search in Google Scholar
  • 31 Nieuwland R, Siljander PR. A beginner's guide to study extracellular vesicles in human blood plasma and serum. J Extracell Vesicles 2024; 13 (01) e12400
    Search in Google Scholar
  • 32 Boilard E. Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA. J Lipid Res 2018; 59 (11) 2037-2046
    Search in Google Scholar
  • 33 Zhao Z, Wijerathne H, Godwin AK, Soper SA. Isolation and analysis methods of extracellular vesicles (EVs). Extracell Vesicles Circ Nucl Acids 2021; 2 (01) 80-103
    Search in Google Scholar
  • 34 Lucchetti D, Battaglia A, Ricciardi-Tenore C. et al. Measuring extracellular vesicles by conventional flow cytometry: dream or reality?. Int J Mol Sci 2020; 21 (17) 6257
    Search in Google Scholar
  • 35 Welsh JA, Van Der Pol E, Arkesteijn GJA. et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J Extracell Vesicles 2020; 9 (01) 1713526
    Search in Google Scholar
  • 36 van der Pol E, Welsh JA, Nieuwland R. Minimum information to report about a flow cytometry experiment on extracellular vesicles: communication from the ISTH SSC subcommittee on vascular biology. J Thromb Haemost 2022; 20 (01) 245-251
    Search in Google Scholar
  • 37 Nielsen T, Kristensen AF, Pedersen S, Christiansen G, Kristensen SR. Investigation of procoagulant activity in extracellular vesicles isolated by differential ultracentrifugation. J Extracell Vesicles 2018; 7 (01) 1454777
    Search in Google Scholar
  • 38 Hisada Y, Sachetto ATA, Mackman N. Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases. Immunol Rev 2022; 312 (01) 61-75
    Search in Google Scholar
  • 39 Bonifay A, Mackman N, Hisada Y. et al. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology. J Thromb Haemost 2024; 22 (10) 2910-2921
    Search in Google Scholar
  • 40 Zong Y, Antovic A, Soutari NMH, Antovic J, Pruner I. Synergistic effect of bypassing agents and sequence identical analogue of emicizumab and fibrin clot structure in the in vitro model of hemophilia A. TH Open 2020; 4 (02) e94-e103
    Search in Google Scholar
  • 41 Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113 (17) 3911-3917
    Search in Google Scholar
  • 42 De Stefano V, Sorà F, Rossi E. et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3 (09) 1985-1992
    Search in Google Scholar
  • 43 Zhang W, Cui Y, Wu J. et al. Incidence and risk factors of venous thromboembolism in patients with acute Leukemia: a systematic review and meta-analysis. Leuk Res 2025; 153: 107694
    Search in Google Scholar
  • 44 Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91 (11) 1530-1537
    Search in Google Scholar
  • 45 Barbui T, Finazzi G, Falanga A, Battista R, Bassan R. Bleeding and thrombosis in acute lymphoblastic leukemia. Leuk Lymphoma 1993; 11 (Suppl. 02) 43-47
    Search in Google Scholar
  • 46 Yanada M, Matsushita T, Asou N. et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007; 78 (03) 213-219
    Search in Google Scholar
  • 47 Nehrbas J, Butler JT, Chen DW, Kurre P. Extracellular vesicles and chemotherapy resistance in the AML microenvironment. Front Oncol 2020; 10: 90
    Search in Google Scholar
  • 48 Khorana AA, Ahrendt SA, Ryan CK. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13 (10) 2870-2875
    Search in Google Scholar
  • 49 Thaler J, Preusser M, Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013; 131 (02) 162-165
    Search in Google Scholar
  • 50 Kwaan HC, Cull EH. The coagulopathy in acute promyelocytic leukaemia–what have we learned in the past twenty years. Best Pract Res Clin Haematol 2014; 27 (01) 11-18
    Search in Google Scholar
  • 51 Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007; 33 (04) 330-338
    Search in Google Scholar
  • 52 Hisada Y, Archibald SJ, Bansal K. et al. Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia. J Thromb Haemost 2024; 22 (07) 1984-1996
    Search in Google Scholar
  • 53 Zhao H, Sun J, Yan L. et al. Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study. Ann Hematol 2021; 100 (06) 1473-1483
    Search in Google Scholar
  • 54 Ma G, Liu F, Lv L, Gao Y, Su Y. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol 2013; 92 (05) 645-652
    Search in Google Scholar
  • 55 Tuckuviene R, Ranta S, Albertsen BK. et al. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. J Thromb Haemost 2016; 14 (03) 485-494
    Search in Google Scholar
  • 56 Tzoran I, Rebibo-Sabbah A, Brenner B, Aharon A. Disease dynamics in patients with acute myeloid leukemia: new biomarkers. Exp Hematol 2015; 43 (11) 936-943
    Search in Google Scholar
  • 57 Van Aalderen MC, Trappenburg MC, Van Schilfgaarde M. et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost 2011; 9 (01) 223-226
    Search in Google Scholar
  • 58 Dicke C, Amirkhosravi A, Spath B. et al. Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol 2015; 4: 22
    Search in Google Scholar
  • 59 Thaler J, Pabinger I, Sperr WR, Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res 2014; 133 (03) 303-305
    Search in Google Scholar
  • 60 Gheldof D, Haguet H, Dogné JM. et al. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis 2017; 43 (02) 224-232
    Search in Google Scholar
  • 61 Date K, Ettelaie C, Maraveyas A. Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. J Thromb Haemost 2017; 15 (12) 2289-2299
    Search in Google Scholar
  • 62 Pluchart C, Barbe C, Poitevin G, Audonnet S, Nguyen P. A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?. J Thromb Thrombolysis 2021; 51 (03) 711-719
    Search in Google Scholar
  • 63 Caruso V, Di Castelnuovo A, Meschengieser S. et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 2010; 115 (26) 5322-5328
    Search in Google Scholar
  • 64 Hohaus S, Bartolomei F, Cuccaro A. et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers (Basel) 2020; 12 (05) 1291
    Search in Google Scholar
  • 65 Li JW, Shi D, Wan XC. et al. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. OncoImmunology 2021; 10 (01) 1995166
    Search in Google Scholar
  • 66 Matthiesen R, Gameiro P, Henriques A. et al. Extracellular vesicles in diffuse large B cell lymphoma: characterization and diagnostic potential. Int J Mol Sci 2022; 23 (21) 13327
    Search in Google Scholar
  • 67 Lazana I. Extracellular vesicles in haematological disorders: a friend or a foe?. Int J Mol Sci 2022; 23 (17) 10118
    Search in Google Scholar
  • 68 Otasevic V, Gran C, Milic N. et al. Extracellular vesicles profile and risk of venous thromboembolism in patients with diffuse large B-cell lymphoma. Int J Mol Sci 2025; 26 (12) 5655
    Search in Google Scholar
  • 69 Georgantopoulos P, Yang H, Norris LB, Bennett CL. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. Cancer Med 2019; 8 (05) 2233-2240
    Search in Google Scholar
  • 70 Barr PM, Robak T, Owen C. et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 2018; 103 (09) 1502-1510
    Search in Google Scholar
  • 71 Lipsky AH, Farooqui MZ, Tian X. et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2015; 100 (12) 1571-1578
    Search in Google Scholar
  • 72 Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8 (20) 1137-1140
    Search in Google Scholar
  • 73 Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006; 108 (08) 2596-2603
    Search in Google Scholar
  • 74 Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009; 145 (02) 151-163
    Search in Google Scholar
  • 75 Leebeek FW, Kruip MJ, Sonneveld P. Risk and management of thrombosis in multiple myeloma. Thromb Res 2012; 129 (Suppl. 01) S88-S92
    Search in Google Scholar
  • 76 Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111 (06) 2962-2972
    Search in Google Scholar
  • 77 Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9 (04) 653-663
    Search in Google Scholar
  • 78 Nomura S, Ito T, Yoshimura H. et al. Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma. J Blood Med 2018; 9: 1-7
    Search in Google Scholar
  • 79 Nielsen T, Kristensen SR, Gregersen H, Teodorescu EM, Christiansen G, Pedersen S. Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma. PLoS One 2019; 14 (01) e0210835
    Search in Google Scholar
  • 80 Nielsen T, Kristensen SR, Gregersen H, Teodorescu EM, Pedersen S. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Thromb Res 2021; 202: 108-118
    Search in Google Scholar
  • 81 Auwerda JJ, Yuana Y, Osanto S. et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105 (01) 14-20
    Search in Google Scholar
  • 82 Charles S, Fatrara T, Bouriche T. et al. Tissue factor-bearing extracellular vesicles, procoagulant phospholipids and D-dimer as potential biomarkers for venous thromboembolism in patients with newly diagnosed multiple myeloma: a comprehensive analysis. Thromb Res 2025; 247: 109256
    Search in Google Scholar
  • 83 Adelborg K, Corraini P, Darvalics B. et al. Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study. J Thromb Haemost 2019; 17 (08) 1305-1318
    Search in Google Scholar
  • 84 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33 (04) 313-320
    Search in Google Scholar
  • 85 Trappenburg MC, van Schilfgaarde M, Marchetti M. et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009; 94 (07) 911-918
    Search in Google Scholar
  • 86 Taniguchi Y, Tanaka H, Luis EJ. et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol 2017; 106 (05) 691-703
    Search in Google Scholar
  • 87 Zhang W, Qi J, Zhao S. et al. Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms. Oncol Lett 2017; 14 (02) 2531-2536
    Search in Google Scholar
  • 88 Aswad MH, Kissová J, Rihova L, Zavrelova J, Ovesná P, Penka M. High level of circulating microparticles in patients with BCR/ABL negative myeloproliferative neoplasm - a pilot study. Klin Onkol 2019; 32 (02) 109-116
    Search in Google Scholar
  • 89 Charpentier A, Lebreton A, Rauch A. et al. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. Haematologica 2016; 101 (09) e365-e368
    Search in Google Scholar
  • 90 Marchetti M, Tartari CJ, Russo L. et al. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 2014; 89 (01) 68-73
    Search in Google Scholar
  • 91 Butel-Simoes LE, Albayati A, Yu J. et al. Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding. J Thromb Thrombolysis 2025
    Search in Google Scholar
  • 92 Théry C, Witwer KW, Aikawa E. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018; 7 (01) 1535750
    Search in Google Scholar
  • 93 Welsh JA, Goberdhan DCI, O'Driscoll L. et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles 2024; 13 (02) e12404
    Search in Google Scholar
  • 94 Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F. The ISTH SSC Workshop. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013
    Search in Google Scholar